This is how the procedure works.
From blood drop to risk assessment.
Early diagnosis increases quality of life.The patented betaSENSE method provides science and pharmaceutics with a new basis for developing therapeutic approaches for neurodegenerative diseases. With the betaSENSE test, in the future there may also be screenings for people aged 65 and over, helping to make early diagnoses and take appropriate measures.
Looking into one’s own future.
Well explained and clearly communicated: The betaSENSE method as seen by journalists – in the ZDF
show “Leschs Kosmos” and the 3sat show “nano” (both in German):
Threat to the control centre of our body:
Whether Alzheimer’s, Parkinson’s or ALS – in each case from the very beginning
on an endogenous protein is produced at elevated rates, which protein changes due to the accumulation and is deposited in the form of plaques in the brain over the course of the disease. The betaSENSE method extracts this protein from body fluids and identifies alterations.
A multifaceted condition.
Parkinson’s is the most common neurodegenerative disease second to Alzheimer’s. It results from a slowly progressive loss of nerve cells in the brain and presents with a variety of syndromes. Parkinson’s disease has a massive impact on the daily lives of affected persons and their family members. Typical symptoms such as dysfunction of the musculoskeletal system, uncontrolled shaking of extremities or rigidity reduce the sufferers’ quality of life.
Demographic change driving case numbers.
The ongoing ageing of the population is causing a rapid increase in the number of cases worldwide, from 2.5 million in 1990 to more than 8.5 million in 2019. About 75 % of Parkinson’s syndromes are idiopathic, i.e. without a clearly identifiable cause. In only about 10–20 % of cases is a genetic background the trigger of the disease. Basically, men are affected slightly more often than women.
Amyotrophic lateral sclerosis (ALS).
Making the correct diagnosis.
The causes of the condition are still largely unknown. One of the biggest risk factors is age. ALS leads to degeneration of nerve cells that are responsible for controlling individual muscle groups. Differentiating ALS from diseases with similar concomitant symptoms is a major challenge.
Precise laboratory tests are crucial.
A mean survival time of about four years after onset of the disease makes it clear that only precise and rapid diagnosis can help affected individuals to counteract amyotrophic lateral sclerosis in time. Meaningful laboratory tests provide important support in the fight against the disease.
You want to get tested?
Currently, the betaSENSE test is awaiting marketing authorisation. If you are interested, you can already put your name on our non-binding “Pre-Registration List”. We will inform you as soon as the test is authorised.
We want to make a dignified life possible – for any person any time, also in old age.
We want to provide certainty – so that affected persons can take targeted preventive action.
We are changing the face of Alzheimer’s – relieving sufferers, families and systems.
We create the basis for innovations in protein diagnostics – so that research and development of new drugs progress.